Real World Evidence (RWE) is playing an important role in the drug development process by providing valuable insights from real world clinical practice. In order to leverage these data effectively and make informed decisions, sponsors need to be aware of the types of data that are available, and the challenges associated with using them, as well as the differences between RWE and clinical trial data and how they can complement each other.
In this seminar, we will introduce different sources of RWE and discuss the challenges and strengths one might encounter in this space. We will showcase solutions of how RWE has been used effectively alongside clinical data and discuss important examples where RWE has been used to provide valuable insights, as a case study.
Date/Time: Tuesday, 19th November 2024, 4pm GMT / 11am EST / 8am PST
Speakers:
• Matthew Thompson (Moderator), Associate Director, Programming, Phastar
• Li Huang, Principal Statistician, Phastar
• Andrew Elders, Senior Statistician, Phastar
• Alice Wang, Associate Director, Data Science, Phastar
Learning Points:
• Harnessing Real World Data (RWD) to generate RWE for regulatory studies
• Leveraging RWE alongside Clinical Trial Data
• Deploying RWE in regulatory decision making
• Analysis of Factors Influencing Treatment Decision Making in Resectable Non-Small Cell Lung Cancer – A RWE Case Study
Complete the form below to watch the recording:
